Drugs / GSK2239633
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01371812 | Mar → Jul 2011 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01086462 | Jan → Feb 2010 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2239633 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01086462 ↗ |
| Known as | GSK 2239633A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178575 ↗ |
| Action | Inhibit | “human chemokine receptor 4 (CCR4) antagonist” NCT01371812 ↗ |
| Modality | Small molecule | — CHEMBL2178575 ↗ |
| Route | Intravenous | “Each subject will receive a single intravenous infusion of 100ug GSK2239633” NCT01086462 ↗ |
| Target | CCR4 | “human chemokine receptor 4 (CCR4) antagonist” NCT01371812 ↗ |